Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Jaime Merchan
- Target Recruit Count
- 36
- Registration Number
- NCT00884676
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- John P. Fruehauf
- Target Recruit Count
- 4
- Registration Number
- NCT00879619
- Locations
- 🇺🇸
Chao Comprehensive Cancer Center, Orange, California, United States
Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2016-07-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT00864864
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 88
- Registration Number
- NCT00861419
Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC
- Conditions
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Noah Hahn, M.D.
- Target Recruit Count
- 9
- Registration Number
- NCT00859339
- Locations
- 🇬🇧
St. Bartholomew's Hospital (Barts), London, United Kingdom
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT00859456
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2020-07-01
- Lead Sponsor
- Amgen
- Target Recruit Count
- 85
- Registration Number
- NCT00853372
Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 10
- Registration Number
- NCT00853125
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-23
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00849186
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00847015
- Locations
- 🇺🇸
Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.